Compare FEIM & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | MYGN |
|---|---|---|
| Founded | 1961 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.3M | 551.8M |
| IPO Year | N/A | 1995 |
| Metric | FEIM | MYGN |
|---|---|---|
| Price | $52.97 | $5.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $42.50 | $11.00 |
| AVG Volume (30 Days) | 237.9K | ★ 877.4K |
| Earning Date | 03-12-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.76 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | $69,852,000.00 | ★ $825,300,000.00 |
| Revenue This Year | $5.52 | $0.03 |
| Revenue Next Year | $17.07 | $5.38 |
| P/E Ratio | $24.38 | ★ N/A |
| Revenue Growth | ★ 16.06 | 0.21 |
| 52 Week Low | $13.69 | $3.76 |
| 52 Week High | $61.47 | $15.47 |
| Indicator | FEIM | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 38.06 |
| Support Level | $51.39 | $5.47 |
| Resistance Level | $59.80 | $6.15 |
| Average True Range (ATR) | 3.53 | 0.36 |
| MACD | -1.32 | -0.02 |
| Stochastic Oscillator | 21.73 | 24.33 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.